Key result
Totally thoracoscopic MV repair in Barlow's disease yields 0 deaths, complications, or recurrent significant MR.
Why the study?
This study aimed to confirm the safety and feasibility of totally thoracoscopic repair for mitral regurgitation in Barlow's disease.
Does totally thoracoscopic mitral valve repair improve clinical and echocardiographic outcomes in patients with mitral regurgitation due to Barlow's disease?
Observational (n=21)
No
Does totally thoracoscopic mitral valve repair improve clinical and echocardiographic outcomes in patients with mitral regurgitation due to Barlow's disease?
Totally thoracoscopic mitral valve repair utilizing leaflet folding, artificial chordae, and ring annuloplasty is a safe and feasible approach for Barlow's disease, yielding excellent mid-term valve function.
Answers are grounded in this paper and cite their sources.
Supports feasibility of totally thoracoscopic repair in Barlow's disease; leaves open need for randomized comparisons to conventional approaches.
Objective This study aimed to confirm the safety and feasibility of totally thoracoscopic repair for mitral regurgitation (MR) in Barlow’s disease. Methods From June 2018 to December 2022, 21 consecutive Barlow's disease patients (aged 33 ± 12 years; 57.1% male) underwent totally thoracoscopic mitral valve (MV) repair with leaflets folding, multiple artificial chordae implantation and ring annuloplasty. The safety and feasibility of this technique was evaluated by its mid-term clinical outcomes. Results There was no operative death or complications. The mean cardiopulmonary bypass (CPB) time was 190 ± 41 (128–267) min, and the aortic cross-clamp time was 145 ± 32 (66–200) min. The average number of artificial chordae implantation was 2.9 ± 0.7 (1–4) pairs. During a mean follow-up time of 25.6 ± 15.2 (1–52) months, all patients showed persistent effective valve function with a mean transvalvular gradient of 1.995 ± 1.543 (1.0–6.0) mmHg and no significant MR (10 cases of mild MR) or systolic anterior motion (SAM). Conclusions Totally thoracoscopic repair was a safe, effective, and reproducible procedure with satisfied mid-term clinical outcomes for MR in Barlow’s disease. However, further randomized and long-term follow-up studies were warranted to determine its clinical effects.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2023) conducted an observational in Mitral regurgitation in Barlow's disease (n=21). Totally thoracoscopic mitral valve repair was evaluated on Operative death, complications, and recurrent moderate or severe mitral regurgitation. Totally thoracoscopic mitral valve repair in patients with Barlow's disease resulted in no operative deaths or complications and no recurrent moderate or severe mitral regurgitation over 25.6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: